Abstract
A high percentage of patients with human immunodeficiency virus infection presents with decreased tryptophan concentrations in serum and cerebrospinal fluid. In parallel degradation products of tryptophan like kynurenine and quinolinic acid are increased. We investigated the behavior of tryptophan concentrations in 14 patients with HIV infection before and during treatment with zidovudine, and we found a significant increase of tryptophan in serum and cerebrospional fluid after 4–14 months of therapy. In parallel, neopterin concentrations decreased signficantly. Moreover, an association existed in cerebrospinal fluid between the degree of tryptophan increase and neopterin decrease. Thus, treatment with zidovudine contributes to a gradual normalization of tryptophan metabolism in patients with HIV-1 infection. The data imply that zidovudine therapy is associated not only with a reduction of virus replication but also immune activation is reduced.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Freese A., Swartz K.J., During M.J. and Martin J.B., 1990, Kynurenine metabolites of tryptophan: Implications for neurologic diseases,Neurology40: 691.
Fuchs D., Hausen A., Reibnegger G., Werner E.R., Dierich M.P. and Wachter H., 1988, Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection,Immunol Today9: 150.
Fuchs D., Moller A.A., Reibnegger G., Stöckle E., Werner E.R., and Wachter H., 1990, Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/ psychiatric symptoms,J Acquir Immune Defic Syndr3: 873.
Fuchs D., Forsman A., Hagberg L., et al., 1990, Immune activation and decreased tryptophan in patients with HIV-1 infection, J Interferon Res 10: 599.
Fuchs D., Werner E.R. and Wachter H., 1992, Soluble products of immune activation: Neopterin. In: Manual of Clinical Laboratory Immunology, 4th edition, R.R. Rose, E.C. deMacario, J.L. Fahey, H. Friedman and G.M. Penn, eds., American Society for Microbiology 251.
Gisslén M., Larsson M., Norkrans G., Fuchs D., Wachter H. and Hagberg L., 1994, Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection, AIDSRes Human Retroviruses10: 947.
Larsson M., Hagberg L., Norkrans G., and Forsman A., 1989, Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection,J Neurosci Res23: 441.
Lipton S.A., 1992, Models of neuronal injury in AIDS: another role for the NMD A receptor?Trends Neurosci15: 75.
Werner E.R., Fuchs D., Hausen A., et al., 1988, Tryptophan degradation in patients infected by human immunodeficiency virus, Biol Chem Hoppe Seyler 369: 337.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Plenum Press, New York
About this chapter
Cite this chapter
Fuchs, D., Gisslen, M., Larsson, M., Norkrans, G., Hagberg, L., Wachter, H. (1996). Increase of Tryptophan in Serum and in Cerebrospinal Fluid of Patients with HIV Infection During Zidovudine Therapy. In: Filippini, G.A., Costa, C.V.L., Bertazzo, A. (eds) Recent Advances in Tryptophan Research. Advances in Experimental Medicine and Biology, vol 398. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0381-7_21
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0381-7_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8026-9
Online ISBN: 978-1-4613-0381-7
eBook Packages: Springer Book Archive